{"version": "20221009", "payload": [{"gene": "3CLpro", "position": 15, "mutations": "3CLpro:G15S", "comment": "G15S is a common polymorphism (prevalence 0.5%) which was present in the Lambda variant. It has been reported to reduce the biochemical activity of nirmatrelvir by 4-fold[^FDA21d]. It has a global prevalence of 0.3%. (Feb 1, 2022)", "date_added": "2022-02-01", "date_updated": "2022-09-28", "": ""}, {"gene": "3CLpro", "position": 21, "mutations": "3CLpro:T21I", "comment": "T21I has been selected during in vitro passage experiments with nirmatrelvir[^Iketani22c][Zhou22c]. It is associated without about 4-fold reduced nirmatrelvir susceptibility[^Iketani22c][Zhou22c]. (Sep 28, 2022)", "date_added": "2022-09-28", "date_updated": "", "": ""}, {"gene": "3CLpro", "position": 49, "mutations": "3CLpro:M49IT", "comment": "M49I is associated with about 12-fold reduced susceptibility to ensitrelvir[^Noske22][^Moghadasi22]. M49T is associated with about 6-fold reduced susceptibility to ensitrelvir[^Noske22]. M49I/T have global prevalences of about 0.02% and 0.001%, respectively. (Sep 28, 2022)", "date_added": "2022-09-28", "date_updated": "", "": ""}, {"gene": "3CLpro", "position": 50, "mutations": "3CLpro:L50F", "comment": "L50F has been selected during in vitro passage experiments with nirmatrelvir alone[^Ikeanit22c] and in combination with E166V[^Zhou22c]. It has been selected in vitro with another Mpro inhibitor (ALG-097161) in combination with E166A+L167F[^Jochmans22]. It is associated with about 2-3-fold reduced nirmatrelvir susceptibility[^Iketani22c][Zhou22c]. M49I has a global prevalence of about 0.05%. (Jun 8, 2022)", "date_added": "2022-06-08", "date_updated": "2022-09-28", "": ""}, {"gene": "3CLpro", "position": 135, "mutations": "3CLpro:T135I", "comment": "T135I is a rare variant (prevalence 0.01%) which has been reported to reduce the biochemical activity of nirmatrelvir by about 4-fold[^FDA21d]. (Feb 1, 2022)", "date_added": "2022-02-01", "date_updated": "2022-09-28", "": ""}, {"gene": "3CLpro", "position": 142, "mutations": "3Clpro:N142DSL", "comment": "N142D/S are associated with 3-5 fold reduced ensiltrevir susceptibility[^Noske22]. N142L has been reported to have both a 0.6-fold[^Hu22b] and 9.4-fold[^Sasi22] reduction in nirmatrelvir susceptibility. The prevalence of these 3 mutations ranges from 0.0003% to 0.001%. (Oct 5, 2022)", "date_added": "2022-10-05", "date_updated": "", "": ""}, {"gene": "3CLpro", "position": 144, "mutations": "3CLpro:S144AFGMY", "comment": "S144A is a substrate cleft mutation which has been selected in vitro by nirmatrelvir in combination with other Mpro mutations[^Iketani22b][^FDA21d]. Alone, it is associated with 1 to 10-fold reduced nitrmatrelvir susceptibility in biochemical and cell culture assays[^Hu22b][^Iketani22c][^Moghadasi22] and a very high fold increase in Ki[^FDA21d]. In combination with other mutations such as T21I, it is associated with much higher reductions in nirmatrelvir susceptibility[^Iketani22c]. It reduces ensitrelvir susceptibility about 8-fold[^Iketani22c]. It is associated with moderately reduced enzymatic function. Its prevalence is 0.00008%. S144FGMY are extremely rare mutations that reduce the nirmatrelvir susceptibility while reducing Mpro enzymatic activity[^Hu22b]. (Feb 1, 2022)", "date_added": "2022-02-01", "date_updated": "2022-10-03", "": ""}, {"gene": "3CLpro", "position": 164, "mutations": "3CLpro:H164N", "comment": "H164N is an extremely rare Mpro mutation (prevalence 0.0004%) in the enzyme substrate cleft that has been reported to reduce the biochemical inhibition of nirmatrelvir about 4-fold[^FDA21d]. (Feb 1, 2022)", "date_added": "2022-02-01", "date_updated": "2022-07-01", "": ""}, {"gene": "3CLpro", "position": 165, "mutations": "3CLpro:M165T", "comment": "M165T reduces the biochemical inhibition of nirmatrelvir about 5-fold while reducing Mpro enzymatic activity[^Hu22b]. Its prevalence is about 0.00007%. (Jul 1, 2022)", "date_added": "2022-07-01", "date_updated": "", "": ""}, {"gene": "3CLpro", "position": 166, "mutations": "3CLpro:E166AQ", "comment": "E166Q reduces nirmatrelvir inhibitory biochemical activity between 1.5 and 10-fold depending on the assay without reducing enzymatic activity[^Hu22b]. It has a prevalence of about <0.00001% E166A in combination with L50V+L167F reduced nirmatrelvir susceptibility >20-fold but the combination was associated a replication capacity of only 15%[^Jochmans22]. E166A has a prevalence of about 0.00004%. (Jun 8, 2022)", "date_added": "2022-06-08", "date_updated": "2022-07-05", "": ""}, {"gene": "3CLpro", "position": 166, "mutations": "3CLpro:E166V", "comment": "E166V has been selected in vitro during passage in the presence of nirmatrelvir in multiple experiments often in combination with L50F[^Zhou22c][^Iketani22b]. E166V has been associated with 25-265-fold reductions in nirmatrelvir susceptibility in multiple different cell lines often without reducing SARS-CoV-2 replication[^Zhou22c][^Iketani22b]. E166V has also been reported in three persons receiving nirmatrelvir in the EPIC-HR trial[^FDA21d]. In nirmatrelvir-naive persons, its prevalence is about 0.00004%. (Oct 3, 2022)", "date_added": "2022-10-03", "date_updated": "", "": ""}, {"gene": "3CLpro", "position": 167, "mutations": "3CLpro:E167F", "comment": "E167F has been selected in vitro during passage in the presence of nirmatrelvir in multiple experiments[^Jochnabs22][^Iketani22]. It is associated with about 5-fold reduced susceptibility to nirmatrelvir[^Heilmann22]. (Oct 5, 2022)", "date_added": "2022-10-05", "date_updated": "", "": ""}, {"gene": "3CLpro", "position": 168, "mutations": "3CLpro:P168del", "comment": "P168 deletions are associated with about 5-fold reductions in susceptibility to nirmatrelvir and ensitrelvir[^Moghadasi22]. (Oct 5, 2022)", "date_added": "2022-10-05", "date_updated": "", "": ""}, {"gene": "3CLpro", "position": 172, "mutations": "3CLpro:H172QYF", "comment": "H172QY are substrate cleft mutations selected in combination with other mutations during in vitro passage in the presence of nirmatrelvir[^Iketani21c]. H172Q is associated with about 6-fold reduced nirmatrelvir susceptibility[^Hu22b]. H172Y is associated with about 25-fold reduced nirmatrelvir susceptibility particularly when it occurs in combination with Q189E[^Hu22b][^Oliveira22][^FDA21d][^Sasi22]. H172Q has about 68% reduced enzymatic activity[^Hu22b]. H172F is associated with about 25-fold reduced nirmatrelvir activity but has 90% reduced enzymatic activity. H172Q has a prevalence of 0.00004%. H172FY have prevalences <0.00001%. (Feb 1, 2022)", "date_added": "2022-02-01", "date_updated": "2022-10-03", "": ""}, {"gene": "3CLpro", "position": 173, "mutations": "3CLpro:A173VT", "comment": "A173V is a substrate cleft mutation frequently selected by nirmatrelvir[^Iketani22c]. It is associated with 2 to 10-fold reductions in nirmatrelvir susceptibility[Zhou22v][^Iketani22c][Moghadasi22]. A173T is associated with about 5-fold reduced nirmatrelvir susceptibility[^Moghadasi22]. A173VT have prevalences of about 0.001%. (Oct 5, 2022)", "date_added": "2022-10-05", "date_updated": "", "": ""}, {"gene": "3CLpro", "position": 186, "mutations": "3CLpro:V186A", "comment": "V186A is a substrate cleft mutation selected in vitro by nirmatrelvir[^Iketani22c]. It has a prevalence of about 0.0005%. (Oct 5, 2022)", "date_added": "2022-10-05", "date_updated": "", "": ""}, {"gene": "3CLpro", "position": 188, "mutations": "3CLpro:R188S", "comment": "R188S is a substrate cleft mutation associated with about 5-fold reduced ensitrelvir susceptibility[^Noske22]. It has a prevalence of about 0.002%. (Oct 5, 2022)", "date_added": "2022-10-05", "date_updated": "", "": ""}, {"gene": "3CLpro", "position": 189, "mutations": "3CLpro:Q189K", "comment": "Q189 is in a flexible loop that closes over the Mpro substrates and potentially interacts with Mpro inhibitors including nirmatrelvir[^Flynn22]. Q189K increases the Ki for nirmatrelvir 92-fold and its susceptibility 9.3-fold[^FDA21d][^Noske22]. Q189E appears to increase the replication of Mpro enzymes containing H172Y[^Hu22b]. Q189K has a prevalence of 0.0006%. (Feb 1, 2022)", "date_added": "2022-02-01", "date_updated": "2022-10-03", "": ""}, {"gene": "3CLpro", "position": 191, "mutations": "3CLpro:A191TV", "comment": "A191TV are substrate cleft mutations associated with about 4-fold reduced ensitrelvir susceptibility[^Noske22]. A191TV have prevalences of about 0.007% and 0.09%, respectively. (Oct 5, 2022)", "date_added": "2022-10-05", "date_updated": "", "": ""}, {"gene": "3CLpro", "position": 192, "mutations": "3CLpro:Q192RKT", "comment": "Q192RKT are extremely rare substrate-cleft mutations with reduced replication fitness that are associated with reduced susceptibility to nirmatrelvir[^Hu22b][^Heilmann22][^Sasi22]. (Oct 5, 2022)", "date_added": "2022-10-05", "date_updated": "", "": ""}, {"gene": "3CLpro", "position": 248, "mutations": "3CLpro:D248E", "comment": "D248E is a rare variant (prevalence 0.01%) which has been reported to reduce the biochemical activity of nirmatrelvir by 4-fold[^FDA21d]. It has a prevalence of about 0.01%. (Feb 1, 2022)", "date_added": "2022-02-01", "date_updated": "2022-10-05", "": ""}, {"gene": "3CLpro", "position": 252, "mutations": "3CLpro:P252L", "comment": "P252L has been selected in vitro by nirmatrelvir and been reported to reduce its susceptibility by about 10-fold[^Iketani22c]. It has a prevalence of about 0.006%. (Oct 5, 2022)", "date_added": "2022-10-05", "date_updated": "", "": ""}, {"gene": "3CLpro", "position": 304, "mutations": "3CLpro:T304I", "comment": "T304I has been selected in vitro by nirmatrelvir and been reported to reduce its susceptibility by about 4-fold[^Iketani22c][^Zhou22c]. It has a prevalence of about 0.009%. (Oct 5, 2022)", "date_added": "2022-10-05", "date_updated": "", "": ""}, {"gene": "nsp6", "position": 106, "mutations": "nsp6:106del, nsp6:107del, nsp6:108del", "comment": "The Alpha, Beta, Gamma, Eta, Iota, Lambda, and Omicron variants each contain the same deletion of amino acids 106 to 108 in the non-structural protein 6 (nsp6) a component of the SARS-CoV-2 membrane-tethered replication complex that is also involved in antagonizes host-responsiveness to interferons[^Annavajhala21][^Martin21][^Skidmore21][^Xia20c][^Plante21]. (Apr 5, 2021)", "date_added": "2021-04-05", "date_updated": "2021-11-27", "": ""}, {"gene": "RdRP", "position": 166, "mutations": "RdRp:V166LA", "comment": "V166L has been selected in vitro by RDV[^Checkmahomed22] and in vivo by RDV one immunocompromised person with prolonged infection[^Heyer22]. It is associated with approximately 2-fold reduced RDV susceptibility. V166L has been reported in approximately 0.004% of published SARS-CoV-2 isolates. V166A has been selected in vitro by RDV in combination with 3 other RdRp mutations[^Stevens22]. (Jun 18, 2022)", "date_added": "2022-06-18", "date_updated": "2022-09-26", "": ""}, {"gene": "RdRP", "position": 323, "mutations": "RdRP:P323L", "comment": "P323L (Orf1b:P314L) emerged in the same virus containing D614G. It has now reached a global prevalence of 95%, which is slightly lower than that of D614G (98%). Its impact on RdRp function has not been well studied. (Jul 21, 2021)", "date_added": "2021-07-21", "date_updated": "2022-07-21", "": ""}, {"gene": "RdRP", "position": 480, "mutations": "RdRP:F480L", "comment": "F480L is a homolog of a mutation that emerged during in vitro RDV passage in a related coronavirus. It has been shown to reduce the susceptibility of SARS-CoV-1 6-fold when present in combination with V557L[^Agostini18]. It has a global prevalence of 0.0002%. (Feb 8, 2022)", "date_added": "2022-02-08", "date_updated": "2022-09-26", "": ""}, {"gene": "RdRP", "position": 484, "mutations": "RdRP:D484Y", "comment": "D484Y has been reported to emerge in one person receiving RDV[^Martinot21]. It has a global prevalence of 0.0008%. Its effect on RDV susceptibility has not been studied. (Feb 8, 2022)", "date_added": "2022-02-08", "date_updated": "2022-09-26", "": ""}, {"gene": "RdRP", "position": 557, "mutations": "RdRP:V557L", "comment": "V557L is a homolog of a mutation that emerged during in vitro RDV passage in a related coronavirus. It has been shown to reduce the susceptibility of SARS-CoV-1 by 6-fold when it occurred in combination with F480L[^Agostini18]. It has a global prevalence of 0.0003%. (Feb 8, 2022)", "date_added": "2022-02-08", "date_updated": "2022-09-26", "": ""}, {"gene": "RdRP", "position": 759, "mutations": "RdRP:S759A", "comment": "S759A has been selected in vitro in the presence of GS-441524, the parent compound of RDV. S759 occurs in the RdRP SDD active site motif and is therefore analogous to the cytosine analog mutations that occur in the YMDD motif of HIV and HBV. In combination with V792I, another GS-441524-selected mutation, it is associated with 7.3 fold reduced GS-441524 susceptibility[^Stevens22]. It has a prevalence <0.00001%. (May 16, 2022)", "date_added": "2022-05-16", "date_updated": "2022-09-26", "": ""}, {"gene": "RdRP", "position": 792, "mutations": "RdRP:V792I", "comment": "V792I has been selected in vitro in the presence of GS-441524, the parent compound of RDV. It is associated with 2.6 fold reduced GS-441524 susceptibility[^Stevens22]. It has also been selected in two immunocompromised patients receiving remdesivir[^Hogan22]. It has a global prevalence of 0.00006% (May 16, 2022)", "date_added": "2022-05-16", "date_updated": "2022-09-26", "": ""}, {"gene": "RdRP", "position": 802, "mutations": "RdRP:E802AD", "comment": "E802D has been selected in vitro when SARS-CoV-2 is cultured in the presence of increasing concentrations of remdesivir[^Szemiel21]. It has also been reported to emerge in a patient with persistent infection despite remdesivir treatment[^Gandhi21]. E802A and E802D reduce susceptibility to remdesivir by 2.1 and 2.5-fold, respectively[^Szemiel21][^Gandhi22]. E802D and E802A have global prevalences of 0.003% and 0.0003%, respectively. (Nov 18, 2021)", "date_added": "2021-11-18", "date_updated": "2022-09-26", "": ""}, {"gene": "S", "position": 13, "mutations": "S:S13I", "comment": "S13I results in reduced binding to multiple NTD-targeting mAbs[^McCallum21b]. (Apr 8, 2021)", "date_added": "2021-04-08", "date_updated": "2022-06-05", "": ""}, {"gene": "S", "position": 18, "mutations": "S:L18F", "comment": "L18F is an NTD mutation present in the Beta and Gamma variants. It is associated with reduced susceptibility to several NTD-binding mAbs but by itself does not appear to reduce CP or VP susceptibility[^Wang21b][^McCallum21]. (Apr 5, 2021)", "date_added": "2021-04-05", "date_updated": "2022-06-05", "": ""}, {"gene": "S", "position": 20, "mutations": "S:T20N", "comment": "T20N is an NTD mutation present in the Gamma variant. It is associated with reduced susceptibility to several NTD-binding mAbs[^Wang21d] (Nov 23, 2021)", "date_added": "2021-11-23", "date_updated": "2022-06-06", "": ""}, {"gene": "S", "position": 69, "mutations": "S:69del, S:70del", "comment": "NTD deletions at positions 69 and 70 have been reported in multiple variants including the Omicron BA.1, BA.4, and BA.5 variants. They are associated with increased virus replication[^Kemp21][^Meng21]. They do not appear to reduce susceptibility to neutralizing mAbs or convalescent plasma[^McCallum21][^Shen21][^Wang21b][^Rees-Spear21]. This deletion prevents the amplification of one of three genomic segments in a commonly used diagnostic PCR assay, resulting in a phenomenon referred to as S-gene target failure (SGTF). (Apr 5, 2021)", "date_added": "2021-04-05", "date_updated": "2022-06-05", "": ""}, {"gene": "S", "position": 80, "mutations": "S:D80A", "comment": "D80A is an NTD mutation present in the Beta variant. It is associated with reduced susceptibility to some NTD-targeting mAbs but not to plasma from convalescent or vaccinated persons[^Wang21b]. (Apr 8, 2021)", "date_added": "2021-04-08", "date_updated": "2022-06-06", "": ""}, {"gene": "S", "position": 141, "mutations": "S:141del, S:142del, S:143del, S:144del, S:145del, S:146del ", "comment": "NTD deletions between positions 141-146 occur in the Alpha and Omicron BA.1 and BA.2 variants. They are associated with resistance to several NTD-binding neutralizing mAbs but do not appear to reduce the neutralizing activity of plasma from convalescent or vaccinated persons[^Li20h][^McCallum21][^Wang21b]. (Apr 5, 2021)", "date_added": "2021-04-05", "date_updated": "2022-06-05", "": ""}, {"gene": "S", "position": 142, "mutations": "S:G142D", "comment": "G142D is a common NTD mutation present in the Delta and Omicron variants that interferes with the neutralization of many NTD-binding mAbs. (Oct 6, 2022)", "date_added": "2022-10-06", "date_updated": "", "": ""}, {"gene": "S", "position": 147, "mutations": "S:K147E", "comment": "K147E is present in BA.2.75. It may contribute to reduced NTD-binding Abs present in human plasma[^Wang22h]. (Oct 6, 2022)", "date_added": "2022-10-06", "date_updated": "", "": ""}, {"gene": "S", "position": 152, "mutations": "S:W152C", "comment": "W152C reduces binding to multiple NTD-targeting mAbs[^McCallum21b]. (Apr 8, 2021)", "date_added": "2021-04-08", "date_updated": "2022-10-06", "": ""}, {"gene": "S", "position": 242, "mutations": "S:242del, S:243del, S:244del", "comment": "NTD deletions between positions 242-244 are present in the Beta variant. They are associated with resistance to several NTD-binding neutralizing mAbs. They have rarely been associated with reduced neutralization activity of plasma from convalescent persons but remain fully susceptible to plasma from vaccinated persons[^McCallum21][^Wang21b][^Wang21f]. (Apr 7, 2021)", "date_added": "2021-04-07", "date_updated": "2021-07-15", "": ""}, {"gene": "S", "position": 247, "mutations": "S:247del, S:248del, S:249del, S:250del, S:252del, S:252del, S:253del", "comment": "This NTD deletion has been reported in the Lambda variant and is associated with greatly reduced susceptibility to several NTD-binding neutralizing Abs. (Jul 15, 2021)", "date_added": "2021-07-15", "date_updated": "2022-06-05", "": ""}, {"gene": "S", "position": 253, "mutations": "S:D253GY", "comment": "D253G/Y are associated with reduced susceptibility to several NTD-targeting mAbs. (Apr 5, 2021)", "date_added": "2021-04-05", "date_updated": "2022-10-06", "": ""}, {"gene": "S", "position": 337, "mutations": "S:P337HLRT", "comment": "P337H/L/R/T are rare mutations. P337L/R are associated with >100-fold reduced SOT susceptibility[^FDA21b][^Cathcart21]. P337H/T are associated with 5-7-fold reduced SOT susceptibility[^FDA21b][^Cathcart21]. P337L is associated with 5-fold reduced susceptibility to IMD[^FDA20]. (Aug 4, 2021)", "date_added": "2021-08-04", "date_updated": "2022-10-06", "": ""}, {"gene": "S", "position": 339, "mutations": "S:G339D", "comment": "G339D is an RBD core mutatiom that is present in the Omicron VOCs. It has a slightly elevated escape fraction (0.048) for SOT in the UW DMS assay but is susceptible to SOT in most neutralization assays. G339H is present in BA.2.75. It does not appear to reduce mAb susceptibility. (Nov 26, 2021)", "date_added": "2021-11-26", "date_updated": "2022-10-06", "": ""}, {"gene": "S", "position": 340, "mutations": "S:E340AKG", "comment": "E340K developed in 5 subjects receiving SOT in the COMET-ICE trial[^FDA21b] but otherwise mutations at this position are extremely rare. E340A/K are associated with >100-fold reduced SOT susceptibility[^FDA21b][^Cathcart21]. E340G is associated with 27-fold reduced SOT susceptibility[^FDA21b][^Cathcart21]. (Aug 4, 2021)", "date_added": "2021-08-04", "date_updated": "2022-10-06", "": ""}, {"gene": "S", "position": 346, "mutations": "S:R346K", "comment": "R346K is present in the Mu (B.1.621) variant and in about 10% of Omicron BA.1 variants (BA.1.1). Alone is associated with >100-fold reduced susceptibility to C135[^Weisblum20]. In the context of Omicron BA.1, it further reduces the susceptibility of CIL 5-10-fold and of ROM susceptibility about 10-fold[^Liu21l]. (Aug 4, 2021)", "date_added": "2021-08-04", "date_updated": "2022-10-06", "": ""}, {"gene": "S", "position": 346, "mutations": "S:R346SIT", "comment": "R346T occurs in the BA.4.6 lineage. It is highly resistant to CIL/TIX (Evusheld)[Wang22j]. R346S/T/I reduce susceptibility to CIL and C135 in vitro and in the UW DMS assay[^Weisblum20][^Muecksch21][^Yi21][^FDA21c]. (Jun 4, 2022)", "date_added": "2022-06-04", "date_updated": "2022-10-06", "": ""}, {"gene": "S", "position": 356, "mutations": "S:K356T", "comment": "K356T occurs in several BA.2 and BA.2.75 sublineages. It is associated with escape from SOT in the UW DMS assay and 6-fold reduced susceptibility[^Cathcart21]. (Oct 5, 2022)", "date_added": "2022-10-05", "date_updated": "", "": ""}, {"gene": "S", "position": 367, "mutations": "S:V367F", "comment": "V367F has been reported to increase ACE2 binding affinity[^Ou21] but it has not been reported to reduce susceptibility to mAbs or polyclonal Abs in convalescent or vaccinee plasma. (Aug 6, 2021)", "date_added": "2021-08-06", "date_updated": "2022-10-06", "": ""}, {"gene": "S", "position": 371, "mutations": "S:S371L", "comment": "S371L is an RBD core mutation present in the Omicron BA.1 variant. It reduces susceptibility to ETE (6.2 to 31-fold), IMD (11 to 74-fold), and SOT (7.4 to 240-fold). (Nov 26, 2021)", "date_added": "2021-11-26", "date_updated": "2022-10-06", "": ""}, {"gene": "S", "position": 371, "mutations": "S:S371F", "comment": "S371F is an RBD core mutation present in the Omicron BA.2, BA.4, and BA.5 variants. It reduces susceptibility to ETE (143 to 630-fold), CAS (14 to 28-fold), IMD (11 to 126-fold), SOT (5.5 to 21-fold), and TIX (6.3 to 31-fold). (Jun 5, 2022)", "date_added": "2022-06-05", "date_updated": "2022-10-06", "": ""}, {"gene": "S", "position": 405, "mutations": "S:D405N", "comment": "D405N is present in the Omicron BA.2, BA.4, and BA.5 variants. It reduces susceptibility to ETE (16 to 26-fold) and CAS (11 to 14-fold). (Jun 5, 2022)", "date_added": "2022-06-05", "date_updated": "2022-10-06", "": ""}, {"gene": "S", "position": 408, "mutations": "S:R408S", "comment": "R408S is present in the Omicron BA.2, BA.4, and BA.5 variants. By itself, it does not appear to reduce susceptibility to any of the clinical stage mAbs. (Jun 5, 2022)", "date_added": "2022-06-05", "date_updated": "", "": ""}, {"gene": "S", "position": 417, "mutations": "S:K417NT", "comment": "K417N/T are ACE2-binding site RBM mutations present in the Beta (K417N), Gamma (K417T), and Omicron (K417N) variants. Both mutations confer >100-fold reduced susceptibility to ETE and ~30-fold reduced susceptibility to CAS. (Apr 5, 2021)", "date_added": "2021-04-05", "date_updated": "2022-10-06", "": ""}, {"gene": "S", "position": 439, "mutations": "S:N439K", "comment": "N439K is an ACE2-binding site mutation that increases ACE2 affinity[^Chen20m][^Starr20][^Thomson21]. It causes high-level resistance to IMD[^Starr21][^Wang21e]. Viruses containing N439K usually retain full susceptibility to convalescent or vaccinee plasma[^Greaney21][^Shen21][^Thomson21]. (Apr 5, 2021)", "date_added": "2021-04-05", "date_updated": "2022-10-06", "": ""}, {"gene": "S", "position": 440, "mutations": "S:N440K", "comment": "N440K is an increasingly common RBD mutation, which is found in each of the Omicron variants and in several previous global lineages. It causes high-level resistance to IMD and C135, two mAbs that bind the RBD core region[^Weisblum20][^Wang21]. It retains susceptibility to SOT, another core-binding mAb [^Cathcart21]. Based on limited data, it does not appear to reduce susceptibility to most convalescent plasma samples[^Wang21]. (Apr 13, 2021)", "date_added": "2021-04-13", "date_updated": "2022-10-06", "": ""}, {"gene": "S", "position": 444, "mutations": "S:K444QNERTM", "comment": "S:K444T/M/N/R have been reported in several BA.2 and BA.4/5 lineages. K444Q/N are extremely rare mutations associated with reduced susceptibility to IMD and C135[^Baum20][^Weisblum20][^Starr21]. K444Q/E/R are associated with >200-fold reduced susceptibility to CIL[^FDA21c] while K444T/M are associated with escape in the UW DMS assay. K444T/M/N/Q are associated with reduced susceptibility to BEB and/or escape in the UW WH1/BA.1/BA.2 DMS assays[^Westendorf22][^FDA22]. (Jul 21, 2021)", "date_added": "2021-07-21", "date_updated": "2022-10-09", "": ""}, {"gene": "S", "position": 445, "mutations": "S:V445APFG", "comment": "S:V445A/P have been reported one or more BA.2 and BA.5 sub-lineages. Multiple V445 mutations confer reduced IMD, CIL, C135, and BEB susceptibility in vitro and in UW DMS assays[^Baum20][^Copin20][^FDA22][^Wesendorf]. V445A is associated with 3-fold reduced SOT susceptibilty[^Cathcart21]. (Aug 4, 2021)", "date_added": "2021-08-04", "date_updated": "2022-10-05", "": ""}, {"gene": "S", "position": 446, "mutations": "S:G446V", "comment": "G446V was reported to occur in 4.5% of CAS/IMD (REGN-COV2) study participants at an allele fraction above 15%[^Copin21]. It causes high-level resistance to IMD and C135[^Rothenberger21][^Weisblum20]. (Apr 10, 2021)", "date_added": "2021-04-10", "date_updated": "2022-10-06", "": ""}, {"gene": "S", "position": 446, "mutations": "S:G446S", "comment": "G446S is a present in Omicron BA.1 and in BA.2.75. It is associated with high-level resistance to IMD and low-level resistance to CIL. It contributes to a greater reduction in CIL/TIX susceptibility relative to BA.2 and to a 4-fold reduction in BEB susceptibility[^Wang22h]. (Jun 4, 2022)", "date_added": "2022-06-04", "date_updated": "2022-10-06", "": ""}, {"gene": "S", "position": 450, "mutations": "S:N450DK", "comment": "N450D occurs in one or more BA.2 and BA.5 subvariants. N450D confers 9-fold reduced susceptiblity to IMD[^Baum20]. N450K confers 9-fold reduced CIL susceptibility[^FDA21c]. (Aug 6, 2021)", "date_added": "2021-08-06", "date_updated": "2022-10-06", "": ""}, {"gene": "S", "position": 452, "mutations": "S:L452R", "comment": "L452R is present in the Delta and Omicron BA.4/5variants. It is associated with reduced susceptibility to several RBM class II mAbs including BAM but not to the other FDA EUA-approved mAbs[^Copin21][^Li20h][^Liu21][^FDA21][^Wang21e]. It has also been associated with reductions in susceptibility to convalescent and vaccinee plasma samples[^Greaney21c][^Ferreira21]. (Apr 5, 2021)", "date_added": "2021-04-05", "date_updated": "2022-10-06", "": ""}, {"gene": "S", "position": 452, "mutations": "S:L452Q", "comment": "L452Q is present in the Lambda and Omicron BA.12.1 variants. By itself, it is associated with about 20-fold reduced susceptibility to ROM and 2-4 fold reduced susceptibility to CAS and IMD[^Tada21d][^Wang22d]. (Jul 15, 2021)", "date_added": "2021-07-15", "date_updated": "2022-10-06", "": ""}, {"gene": "S", "position": 453, "mutations": "S:Y453F", "comment": "Y453F is an ACE2-binding site RBD mutation that emerged several times in mink lineages, including one that subsequently spread among humans, which is no longer active[^Garcia-Beltran21]. Y453F increases ACE2 binding[^Bayarri-Olmos21][^Gobeil21b][^Starr20]. it confers high-level resistance to CAS[^Baum20][^Wang21f]. (Apr 5, 2021)", "date_added": "2021-04-05", "date_updated": "2022-10-06", "": ""}, {"gene": "S", "position": 455, "mutations": "S:L455F", "comment": "L455F is a rare mutation that reduces susceptibility to CAS and C144[^Baum20][^Copin21][^Weisblum20][^Muecksch21]. (Aug 6, 2021)", "date_added": "2021-08-06", "date_updated": "2022-10-06", "": ""}, {"gene": "S", "position": 460, "mutations": "S:N460KST", "comment": "N460K occurs in BA.2.75. It confers reduced susceptibility to AMU and other class 1 and 2 mAbs, particularly within the context of BA.2 variants[^Wang22h]. N460T is an essentially unreported mutation that has been selected in vitro by ETE and been found to reduce ETE susceptibility >100-fold. (Aug 7, 2021)", "date_added": "2021-08-07", "date_updated": "2022-10-06", "": ""}, {"gene": "S", "position": 477, "mutations": "S:S477N", "comment": "S477N is a common RBD mutation present in the each of the Omicron variants. It increases the strength of ACE2 binding[^Starr20][^Zahradnik21]. It has not been shown to reduce susceptibility to any of the clinical stage mAbs[^Copin21][^Wang21f]. (Apr 5, 2021)", "date_added": "2021-04-05", "date_updated": "2022-10-06", "": ""}, {"gene": "S", "position": 478, "mutations": "S:T478K", "comment": "T478K is an RBD mutation present in the Delta variant and in each of the Omicron variants. It does not appear to reduce to any of the clinical stage mAbs or to convalescent of vaccinee plasma. (Apr 8, 2021)", "date_added": "2021-04-08", "date_updated": "2022-10-06", "": ""}, {"gene": "S", "position": 484, "mutations": "S:E484K", "comment": "E484 is recognized by a high proportion of the polyclonal Abs developing in SARS-CoV-2 infected persons[^Greaney21]. E484K was present in the Beta and Gamma variants. E484K has been selected in vitro by BAM, CAS, and several other class I and II mAbs[^Baum20][^Greaney20][^Liu21][^FDA21][^Weisblum20] and it reduces susceptibility to these mAbs[^Baum20][^Chen21][^Copin21][^Gottlieb21][^Wang21b]. It confers 2.4- to 5.4-fold reduced susceptibility to CIL/TIX (Evusheld)[^FDA21c]. E484K is associated with reduced susceptibility to plasma from previously infected and vaccinated persons[^Greaney20][^Jangra21][^Liu21][^Tada21][^Wang21b]. (Apr 5, 2021)", "date_added": "2021-04-05", "date_updated": "2022-10-06", "": ""}, {"gene": "S", "position": 484, "mutations": "S:E484Q", "comment": "E484 is recognized by a high proportion of the polyclonal Abs developing in SARS-CoV-2 infected persons[^Greaney21]. E484Q is associated with reduced susceptibility to plasma samples from previously infected and vaccinated persons[^Greaney21][^Ferreira21]. (Apr 7, 2021)", "date_added": "2021-04-07", "date_updated": "2022-10-06", "": ""}, {"gene": "S", "position": 484, "mutations": "S:E484A", "comment": "E484 is recognized by a high proportion of the polyclonal Abs developing in SARS-CoV-2 infected persons[^Greaney21]. E484A is present in each of the Omicron variants. It has been selected in vitro by several mAbs and in vivo by BAM[^Peiffer-Smadja21] and CAS/IMD[^Choi20]. It causes high-level resistance to BAM/ETE and low-level resistance to CAS/IMD, and TIX. (Aug 7, 2021)", "date_added": "2021-08-07", "date_updated": "2022-10-06", "": ""}, {"gene": "S", "position": 486, "mutations": "S:F486VS", "comment": "F486V is present in the Omicron BA.4 and BA.5 variants. It has also been selected in vitro by CAS and been shown to reduce BAM/ETE and CAS susceptibility >100-fold and CIL/TIX susceptibility about 10-fold. F486S is associated with high-level resistance to CIL and TIX. (Aug 7, 2021)", "date_added": "2021-08-07", "date_updated": "2022-10-06", "": ""}, {"gene": "S", "position": 490, "mutations": "S:F490S", "comment": "F490S has been reported in several Alpha variant sublineages[^Grabowski21] and in the Lambda variant. It is associated with high-level resistance to BAM but retains susceptibility to the other FDA EUA-approved mAbs[^Gottlieb21][^FDA21]. (Apr 5, 2021)", "date_added": "2021-04-05", "date_updated": "2022-10-06", "": ""}, {"gene": "S", "position": 493, "mutations": "S:Q493KR", "comment": "Q493R/K have been selected in vitro by CAS, BAM and have been reported in patients with prolonged SARS-CoV-2 infections. Both are associated with high-level resistance to BAM/ETE and CAS. Q493R is present in each of the Omicron variants. (Apr 8, 2021)", "date_added": "2021-04-08", "date_updated": "2022-10-06", "": ""}, {"gene": "S", "position": 494, "mutations": "S:S494P", "comment": "S494P has been reported to arise independently in multiple lineages. It confers reduced BAM susceptibility. (Apr 5, 2021)", "date_added": "2021-04-05", "date_updated": "2022-10-06", "": ""}, {"gene": "S", "position": 496, "mutations": "S:G496S", "comment": "G496S is present in the Omicron BA.1 variant but not in the BA.2 and BA.4/5 variants. It is associated with about 5-fold reduced IMD susceptibility. (Oct 6, 2022)", "date_added": "2022-10-06", "date_updated": "", "": ""}, {"gene": "S", "position": 498, "mutations": "S:Q498HR", "comment": "Q498R is present in each of the Omicron variants. It has been selected in vitro for higher ACE2 binding affinity particularly in combination with N501Y[^Zahradnik21]. It does not appear to reduce mAb susceptibility. Q498H is a rare RBD mutation which appears to increase binding to both the human[^Starr20] and mouse[^Huang21] ACE2 receptor. (Jul 15, 2021)", "date_added": "2021-07-15", "date_updated": "2022-10-06", "": ""}, {"gene": "S", "position": 501, "mutations": "S:N501Y", "comment": "N501Y is an ACE2-binding site mutation present in the Alpha, Beta, Gamma, and each of the Omicron variants. It increases ACE2-binding[^Cheng21][^Liu21c][^Starr20][^Supasa21][^Zhu21]. It does not influence the binding and neutralization of most mAbs[^Chen21][^Copin21][^Rees-Spear21][^Shen21][^Wang21b][^Weisblum20]. N501Y alone is rarely associated with reduced susceptibility to plasma from previously infected and/or vaccinated persons[^Edara21][^Rees-Spear21][^Shen21][^Wang21b][^Muik21][^Xie21]. (Apr 5, 2021)", "date_added": "2021-04-05", "date_updated": "2022-10-06", "": ""}, {"gene": "S", "position": 570, "mutations": "S:A570D", "comment": "A570D is in S1 C-terminal domain mutation present in the Alpha variant. It does not reduce susceptibility to any of the mAbs in advanced clinical development or to plasma from convalescent or vaccinated persons[^Wang21b]. (Apr 7, 2021)", "date_added": "2021-04-07", "date_updated": "2021-07-15", "": ""}, {"gene": "S", "position": 614, "mutations": "S:Q613H", "comment": "Q613H occurred in the A.23.1 variant. It was hypothesized to have an effect similar to D614G. (Jul 15, 2021)", "date_added": "2021-07-15", "date_updated": "2022-06-05", "": ""}, {"gene": "S", "position": 614, "mutations": "S:D614G", "comment": "D614G began increasing in prevalence in late February 2020 and within several months rose to a global prevalence approximating 100%[^Korber20]. Virus clones containing D614G produce higher levels of replication in primary human airway cells and in the upper respiratory tracts of hamsters[^Hou20][^Plante20][^Zhou21d]. D614G disrupts one or more interprotomer contacts resulting in a greater likelihood that one or more of the three RBDs are in an open versus closed position[^Benton20][^Yurkovetskiy20]. D614G may also be responsible for increasing the number of spike proteins per virion[^Jackson20][^Zhang20h] and increasing the rate of S1/S2 cleavage[^Gobeil21]. In some studies, viruses with D614G have been slightly more susceptible to neutralization by mAbs, convalescent plasma, and plasma from vaccinated persons[^Weissman21][^Yurkovetskiy20] while in other studies they were slightly more resistant to neutralization[^Hou20][^Zou21]. (Apr 5, 2021)", "date_added": "2021-04-05", "date_updated": "2021-07-15", "": ""}, {"gene": "S", "position": 655, "mutations": "S:H655Y", "comment": "H655Y occurs in the Gamma and Omicron variants and many other SARS-CoV-2 lineages. It increases spike protein cleavage and replication in vitro[^Escalera21]. (Sep 9, 2021)", "date_added": "2021-09-09", "date_updated": "2022-06-04", "": ""}, {"gene": "S", "position": 675, "mutations": "S:Q675HR, S:Q677HP, S:N679K", "comment": "Mutations just upstream of the S1/S2 furin cleavage including Q675H/R, Q677H/P, and N679K have occurred independently in many SARS-CoV-2 global lineages[^Hodcroft21]. Q677H has been shown to increase viral infectivity and syncytia formation and to enhance resistance to neutralization by variants with RBD mutations[^Zeng21]. (Apr 5, 2021)", "date_added": "2021-04-05", "date_updated": "2021-07-15", "": ""}, {"gene": "S", "position": 681, "mutations": "S:P681HR", "comment": "P681H is proximal to the S1/S2 furin cleavage site. It is present in in the Alpha, Theta, and each of the Omicron variants. P681R is present in the Delta and Kappa variants. The increased positive charge associated with both mutations appears to influence virus tropism by increasing S1/S2 cleavage in human airway epithelial cells[^Brown21][^Johnson21][^Lubinsky21][^Frazier21]. (Apr 7, 2021)", "date_added": "2021-04-07", "date_updated": "2022-06-05", "": ""}, {"gene": "S", "position": 701, "mutations": "S:A701V", "comment": "A701V has been reported in several previous circulating variants. It does not appear to reduce susceptibility to any mAb or to plasma from convalescent or vaccinated persons[^Wang21b]. (Apr 8, 2021)", "date_added": "2021-04-08", "date_updated": "2022-06-05", "": ""}, {"gene": "S", "position": 716, "mutations": "S:T716I", "comment": "T716I is an S2 mutation present in the Alpha variant. It does not reduce susceptibility to any of the mAbs in advanced clinical development or to plasma from convalescent or vaccinated persons[^Wang21b]. (Apr 7, 2021)", "date_added": "2021-04-07", "date_updated": "2021-07-15", "": ""}, {"gene": "S", "position": 982, "mutations": "S:S982A", "comment": "S982A is in the heptad repeat 1 part of S2. It is present in the Alpha variant. It does not reduce susceptibility to any of the mAbs in advanced clinical development[^Wang21b]. It minimally reduced susceptibility to a small proportion of convalescent plasma samples[^Wang21b]. (Apr 7, 2021)", "date_added": "2021-04-07", "date_updated": "2021-07-15", "": ""}, {"gene": "S", "position": 1118, "mutations": "S:D1118H", "comment": "D1118H is an S2 mutation present in the Alpha variant. It does not reduce susceptibility to any of the mAbs in advanced clinical development or to plasma from convalescent or vaccinated persons[^Wang21b]. (Apr 7, 2021)", "date_added": "2021-04-07", "date_updated": "2021-07-15", "": ""}, {"gene": "N", "position": 3, "mutations": "N:D3L", "comment": "N:D3L is a mutation in the Alpha variant that has been shown to introduce an enhanced transcription regulator sequence upstream of Orf9b, an IFN antagonist expressed as an alternative reading frame within the nucleocapsid coding region[^Thorne21]. (Jul 15, 2021)", "date_added": "2021-07-15", "date_updated": "2021-11-27", "": ""}, {"gene": "N", "position": 203, "mutations": "N:R203K, N:G204R", "comment": "N:R203K/G204R is a recurrent double amino acid mutation resulting from an adjacent 3-nucleotide change in the nucleocapsid gene. It likely arose by homologous recombination of the core sequence of the leader transcription regulatory sequence and it least to novel sub-genomic transcripts that have been hypothesized to antagonize host innate immunity[^Leary21]. (Jul 15, 2021)", "date_added": "2021-07-15", "date_updated": "", "": ""}]}